Wierda W G, Kipps T J
Department of Medicine, University of California, San Diego, La Jolla 92093-0663, USA.
Curr Opin Hematol. 1999 Jul;6(4):253-61. doi: 10.1097/00062752-199907000-00010.
Significant strides have been made in our understanding of the biology and treatment of B cell chronic lymphocytic leukemia. Recent studies have defined cytogenetic and molecular lesions that may be responsible for leukemogenesis or disease progression. Molecular analyses of immunoglobulin genes have delineated two or more subgroups of chronic lymphocytic leukemia that may differ in their clinical behavior. Research in the biochemistry of chronic lymphocytic leukemia has provided insight into the noted resistance of leukemia cells to cytotoxic drugs. Investigations into the immunology has revealed mechanisms whereby chronic lymphocytic leukemia cells can contribute to the immune deficiency that commonly develops in patients with this disease. Clinical studies have delineated factors that are helpful in predicting prognosis and have provided data on promising new therapies for patients with this disease, including stem cell transplantation, monoclonal antibodies, and gene therapy.
我们对B细胞慢性淋巴细胞白血病的生物学特性及治疗方法的理解取得了重大进展。近期研究已明确了可能导致白血病发生或疾病进展的细胞遗传学和分子损伤。对免疫球蛋白基因的分子分析已划分出两个或更多慢性淋巴细胞白血病亚组，它们的临床行为可能有所不同。慢性淋巴细胞白血病的生物化学研究为白血病细胞对细胞毒性药物的显著耐药性提供了深入见解。免疫学研究揭示了慢性淋巴细胞白血病细胞导致该病患者常见免疫缺陷的机制。临床研究已明确有助于预测预后的因素，并提供了有关针对该病患者的有前景新疗法的数据，包括干细胞移植、单克隆抗体和基因治疗。
